Search
Close this search box.

COST ACTION CA21153

Network for implementing multiomic approaches in atherosclerotic cardiovascular disease prevention and research

Description of the Action

AtheroNET aims to consolidate and connect experts from different fields into European and international network that will focus on the use of multiple omics technologies and data integration through machine learning/artificial intelligence ML/AI approach to bring novel paradigms in prevention, diagnosis, and treatment of atherosclerotic cardiovascular disease (ASCVD).

The latest epidemiological data suggest that cardiovascular diseases (CVD) are still the leading cause of morbidity and mortality worldwide. In order to improve the CVD outcomes, we need new strategies that incorporate the complex interplay of different driving forces behind atherosclerosis pathophysiology in addition to the traditional risk factors.

Meet the Working Groups

Pathophysiological mechanisms in atherosclerosis

WG1 (Co)-Leaders:

  • Dimitris Kardassis
  • Tijana Mitić
  • Nuria Amigo

Personalized models for clinical applications in ASCVD

WG2 (Co)-Leaders:

  • Alberico Catapano
  • Luis Masana
  • Liv Tybjærg Nordestgaard

Standardization and harmonization of research

WG3 (Co)-Leaders:

  • Marie Mardal
  • David de Gonzalo Calvo
  • Fabio Trindade

Data integration and ML/AI

WG4 (Co)-Leaders:

  • Aleksandra Gruca
  • Artemis Hatzigeorgiou
  • Baiba Vilne

Dissemination and communication

WG5 (Co)-Leaders:

  • Georgios Kararigas
  • Brooke Wolford
  • Zulema Rodriguez Hernandez

Latest Updates

Transcriptional regulation of cardiovascular gene expression” held by Dimitris Kardassis, Professor of Biochemistry at the...
Play Video
Dr. Diez Benavente is an Assistant Professor in Experimental Cardiology at the UMC Utrecht (Netherlands)....
Florence Pinet, Institut Pasteur de Lille, University of Lille
Play Video
A full-time, fully funded, research position as senior post-doctoral fellow for 3 years is available...
Principal Investigator NOEMI ROTLLAN discussing new approaches to inhibit miRNAs in an atherosclerosis pre-clinical model.
Play Video
Explore the clinical potential of circRNA with Dr Fabio Martelli, director of the Molecular Cardiology...
Play Video

Learn how we helped 100 top brands gain success